SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors

Folia Histochemica et Cytobiologica

Volumn 48, Issue 1, 2010, Pages 142-147

  Pisarek, Hanna ^a   Pawlikowski, Marek ^a   Kunert Radek, Jolanta ^a   Kubiak, Robert ^a   Winczyk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Immunohistochemistry; Neuroendocrine tumors; Somatostatin receptor subtypes

Indexed keywords

ANGIOPEPTIN; ANTIBODY; KE 108; OCTREOTIDE; PASIREOTIDE; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOPLASM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 77954353625     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0103-7     Document Type: Article

References (36)

1. Meeñ-Mucha G, Mucha S. Somatostatin Receptors: Distribution in Normal Tissues and Transduction Mechanisms. In: Somatostatin Analogs in Diagnostics and Therapy. Edited by Marek Pawlikowski, Landes Bioscience. 2007, pp. 7-20.
2. Cordoba-Chacon J, Luque RM, Gahete MD et al. Identification and molecular characterization of new somatostatin receptor subtype 5 truncated isoforms in rodents. Endocr Abstracts. 2008;16: P463.
3. Reisine T, Bell G. Molecular Biology of Somatostatin Receptors. Endocr Rev. 1995;16:427-442.
4. de Herder WW, Hofland LJ, Van der Lely AJ et al. Somastostatin Receptors in gastroenteropancreatic neuroendocrine tumours. Endocr Rel Cancer. 2003;10:451-458.
5. Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [ 111In- DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
6. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide: state of the art and perspectives. Q J Nucl Med. 2000;44:88-95.
7. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol. 2002;14:38-45.
8. de Herder WW, Kwekkeboom DJ, Feelders RA et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary. 2006;9:243-248.
9. Virgolini I, Patri P, Novotny C et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2000;12(Suppl.2):S41-S45.
10. Kamiñski G, Szaluoe N, Pietrzykowski J et al. Somatostatin receptor scintigraphy with 99mTc-HYNIC-TATE and computed tomography in accurate visualisation of neuroendocrine tumours (NETS). Pol J Endocrinol. 2005;56:S11-4.
11. Hubalewska-Dydejczyk A, Szybiñski P, Fross-Baron K et al. (99m)Tc-EDDA/HYNIC-octreotate- a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur. 2005;8:155-156.
12. Zatelli MC, Piccin D, Bondanelli M et al. An in vivo OctreoScan- negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro. Horm Metab Res.2003;35:349-54.
13. Kunert-Radek J, Biernacka A, Dobaczewski M, Pisarek H, Pawlikowski M, Kuoemierek J. Immunohistochemistry and scintigraphy of somatostatin receptors in patients with neuroendocrine tumors. ENEA 2006, 12th Meeting of the European Neuroendocrine Association. Hormones. Int J Endocrinol Metab. 2006;5:Suppl.1:P181.
14. Hofland LJ, Lamberts SWJ. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12:(Suppl. 2): S31-S36.
15. Pawlikowski M. The incidence of somatostatin receptors in human neoplasms in the light of ex vivo-in vitro studies. Pol J Endocrinol. 2006;57:238-243.
16. Pawlikowski M. Somatostatin Receptors in Human Tumors- In Vitro Studies. In: Somatostatin Analogs in Diagnostics and Therapy. Edited by Marek Pawlikowski, Landes Bioscience. 2007, pp. 39-46.
17. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A. Immunohistochemical Detection of Somatostatin Receptor Subtypes in "Clinically Nonfunctioning" Pituitary Adenomas. Endocrine Pathol. 2003;14:231-238.
18. Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M. Expression of somatostatin receptor subtypes in human pituitary adenomas - immunohistochemical studies. Pol J Endocrinol, 2009;4:240-251.
19. Pisarek H, Stêpieñ T, Kubiak R, Pawlikowski M. Somatostatin receptors in human adrenal gland tumors - immunohistochemical study. Folia Histochem Cytobiol. 2008;46:251-257.
20. Pisarek H, Stêpieñ T, Kubiak R, Borkowska E, Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res. 2009;2:1.
21. Schulz S, Schulz St, Schmitt J et al. Immunocytochemical Detection of Somatostatin Receptors sst1, sst2A and sst3 in Paraffin - embedded Breast Cancer Tissue Using Subtype - specific Antibodies. Clin Cancer Res. 1998;4:2047-2052.
22. Oberg K, Kvols L, Caplin M et al. Consensus report of the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
23. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846.
24. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M. Immunohistochemical Expression of Somatostatin Type 2A Receptor in Neuroendocrine Tumors. Clin Cancer Res. 1999;5:3483-3487.
25. Nasir A, Stridsberg M, Strosberg J et al. Somatostatin Receptor Profiling in Hepatic Metastases From Small Intestinal and Pancreatic Neuroendocrine Neoplasms: Immunohistochemical Approach With Potential Clinical Utility. Cancer Control. 2006;13:52-60.
26. Kulaksiz H, Eissele R, Rossler D et al. Identification of somatostatin receptors subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52-60.
27. Papotti M, Bongiovanni M, Volante M, Landolfini EA, Helboe L, Schindler M. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
28. Mundschenk J, Unger N, Schulz S, et al. Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy. J Clin Endocrinol Metab. 2003;88:5150- 5157.
29. Schulz S, Schmitt J, Quednow C et al., Immunohistochemical Detection of Somatostatin Receptors in Human Ovarian Tumors. Gynecol Oncol. 2002:84:235-240.
30. Taniyama Y, Suzuki T, Mikami Y, Moryia T, Satomi S, Sasano H. Systemic distribution of somatatostatin receptor subtypes in human: an immunohistochemical study. Endocrine J. 2005; 52:605-611.
31. Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest. 1997;27:639-644.
32. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR 1, SSTR 2 and SSTR 3 messenger RNAs in pituitary human tumors using in situ hybridization. Cancer Res. 1994;54:3455-3459.
33. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumors. Eur J Clin Invest. 1998;28:1038-1049.
34. Reubi JC, Waser B, Liu Q et al. Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location. J Clin Endocrinol Metab. 2000;85: 3882-3891.
35. Volante M, Brizzi MP, Faggiano A et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20:1172-1182.
36. Faggiano A, Volante M, Brizzi MP et al. Somatostatin receptor immunohistochemistry in neuroendocrine tumors: a proposal of scoring system for clinical characterization and therapy selection. Endocr Abstracts. 2007;14:P168.